These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8117437)

  • 1. A European collaborative study to assess the proficiency of laboratory estimates of potency of live measles, mumps and rubella tri-valent vaccines.
    Forsey T; Heath AB; Minor PD
    Biologicals; 1993 Sep; 21(3):239-49. PubMed ID: 8117437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical safety issues of measles, mumps and rubella vaccines.
    Afzal MA; Minor PD; Schild GC
    Bull World Health Organ; 2000; 78(2):199-204. PubMed ID: 10743285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in potency assay of measles-mumps-rubella trivalent vaccine: interference between components and measures for its elimination.
    Umino Y; Saito S; Fukuda A; Hishiyama M; Sugiura A
    J Virol Methods; 1990 Feb; 27(2):159-68. PubMed ID: 1690744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Certain problems with limits of immunity against measles, mumps and rubella].
    Magdzik W
    Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference between strains in live virus vaccines, I: Combined vaccination with measles, mumps and rubella vaccine.
    Berger R; Just M; Glück R
    J Biol Stand; 1988 Oct; 16(4):269-73. PubMed ID: 3198657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer viral vaccines: measles, mumps and rubella.
    Krugman S
    Schweiz Rundsch Med Prax; 1975 Feb; 64(5):124-8. PubMed ID: 1215313
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunocytochemical focus assay for potency determination of measles-mumps-rubella trivalent vaccine.
    Fukuda A; Hishiyama M; Umino Y; Sugiura A
    J Virol Methods; 1987 Mar; 15(4):279-84. PubMed ID: 2438297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
    Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The value of the first and second measles-mumps-rubella immunization according to the STIKO (Permanent Immunization Committee) recommendations. Interview by Marianne E Tippmann].
    Stück B
    Kinderkrankenschwester; 2000 Jan; 19(1):25-7. PubMed ID: 10734856
    [No Abstract]   [Full Text] [Related]  

  • 12. Stability characteristics of freeze-dried human live virus vaccines.
    Cowdery S; Frey M; Orlowski S; Gray A
    Dev Biol Stand; 1976 Oct; 36():297-303. PubMed ID: 1030428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of pestivirus RNA in human virus vaccines.
    Harasawa R; Tomiyama T
    J Clin Microbiol; 1994 Jun; 32(6):1604-5. PubMed ID: 8077414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potency estimation of measles, mumps and rubella trivalent vaccines with quantitative PCR infectivity assay.
    Schalk JA; de Vries CG; Jongen PM
    Biologicals; 2005 Jun; 33(2):71-9. PubMed ID: 15939284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
    King SM; Saunders EF; Petric M; Gold R
    Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A collaborative study to assess the proficiency of laboratory estimates of potency of live measles vaccines.
    Forsey T; Heath AB; Minor PD
    Biologicals; 1992 Sep; 20(3):233-42. PubMed ID: 1457108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACIP issues recommendations to eliminate measles, rubella and congenital rubella syndrome and to control mumps.
    Rose VL
    Am Fam Physician; 1998 Nov; 58(7):1682, 1685-6. PubMed ID: 9824963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.